INNATE PHARMA SA-SPONS ADR (IPHA)
US45781K2042 - ADR
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Biggest stock movers today: Innate Pharma, bluebird bio and more
Stock futures were little changed on Tuesday after the major averages extended gains in the last session, as Fed officials attempt to rein in bets for earlier and deeper-than-expected rate..
Innate Pharma and Sanofi to license natural killer cell engager (NASDAQ:IPHA)
Innate Pharma and Sanofi enter licensing agreement for a natural killer cell engager program in solid tumors, offering potential advancements in cancer...
Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi (NASDAQ:IPHA)
Innate Pharma and Sanofi enter licensing agreement for a natural killer cell engager program in solid tumors, offering potential advancements in cancer...
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Innate Pharma CEO Mahjoubi to leave company (NASDAQ:IPHA)
Innate Pharma (NASDAQ:IPHA) said Monday that Mondher Mahjoubi has resigned from his position as CEO and chairman, effective as of January 2024.Hervé Brailly...
Innate Pharma Announces Leadership Change
Innate Pharma to Host Virtual KOL Event on Lacutamab
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
Innate Pharma 2024 Financial Calendar
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
Innate Pharma stock slips on FDA clinical hold (NASDAQ:IPHA)
Innate Pharma stock drops as FDA imposes partial clinical hold on two trials for lymphoma candidate lacutamab, after a fatal rare blood disorder. Read more here.
